NetworkNewsBreaks Archive - Page 2043 of 2141

ThursdayJun 01, 2017 3:10 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) to Provide Update on Pivotal Phase 2b/3 Trial with PRO 140

CytoDyn (OTCQB: CYDY) today announced that its vice chairman and chief science officer, Denis R. Burger, Ph.D, will later this week provide an update on the pivotal Phase 2b/3 trial with PRO 140 as a combination therapy in treatment-experienced HIV patients at the ASM Microbe 2017 Conference. An abstract of the pivotal Phase 2b/3 study is expected to be available online after the conference concludes. To date, PRO 140 has been evaluated in more than 300 HIV patients in various studies. It has shown potent antiviral activity with HIV patients infected with the R5 strain of HIV, which accounts for…

ThursdayJun 01, 2017 12:41 pm

NetworkNewsBreak – Player’s Network, Inc.’s (PNTV) Green Leaf Subsidiary Receives Two Nevada Recreational Marijuana Licenses

Player’s Network (OTCQB: PNTV) has received its recreational marijuana licenses, issued by the State of Nevada, which permits the company to supply recreational marijuana products to retail dispensaries based in the state. The company’s achievement comes two days after the company said it received two state-issued medical licenses to operate its 27,000-square-foot facility in North Las Vegas. Green Leaf Farms Holdings, LLC, the company’s subsidiary, has now met all requirements to begin selling to the recreational market and is anticipated to be able to distribute marijuana to Nevada dispensaries with the new licenses as soon as July 1, 2017. "Qualifying…

ThursdayJun 01, 2017 12:21 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 1, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SPI 39.26% – News: Enters agreement to sell UK solar project; receives minimum bid price notice from NASDAQ CCIH 24.57% – News: Receives license from the Chinese Government to continue providing CDN services ABWN 10.23% – News: Completes proof of concept flight tests in Roswell, New Mexico GBSN 9.68% – News: Presenting at ASM Microbe 2017 June 2-3 CFRX 8.33% – News: Presenting at ASM Microbe 2017 June 2-3 DREM 8.33% – News: Forms…

ThursdayJun 01, 2017 9:16 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Reserves Spot at 6th Annual SeeThru Equity Microcap Investor Conference

ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that it will attend the 6th Annual SeeThru Equity Microcap Investor Conference in New York City today. Warren Wang, founder and CEO of CIIX, stated, “Recently, the firm increased CIIX's price target to $3.75... In addition, SeeThru Equity also gave CIIX a forecast for revenue from its hemp business, projecting the revenue could grow from $0.7 million in FY2017 to reach 8-digit sales by FY2020E, with continued growth thereafter. We sincerely encourage you to come to our booth at the SeeThru Equity Microcap Investor Conference to learn more about CIIX and the incredible…

ThursdayJun 01, 2017 9:05 am

NetworkNewsBreaks – Net Element, Inc.’s (NASDAQ: NETE) PayOnline Subsidiary Partners with International Mobile Network Operator, V-Tell

Net Element's (NASDAQ: NETE) PayOnline subsidiary has launched payment acceptance for V-Tell, marking the start of a partnership that NETE says highlights its position as a global payment acceptance platform and showcases its capabilities to facilitate cross-border transactions through a comprehensive range of services. "We are excited about our partnership with Net Element as we utilize multiple payment methods available through the PayOnline platform, including recurring billing and one-click payment solutions for our website and mobile application," Felix Vakhovsky, CEO and president of V-Tell Group of Companies, stated in the new release. "We are also pleased with the host of…

ThursdayJun 01, 2017 8:38 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage with $0.65 PT on Innovus Pharmaceuticals, Inc. (OTCQB: INNV)

SeeThruEquity has issued an update and $0.65 price target on shares of Innovus Pharmaceuticals, Inc. (OTCQB: INNV) following the company's launch of AllerVarx™ in the U.S. and the report of financial results for the first quarter of 2017. Highlights from the report include revenue of $2.2 million, a 865% increase compared to $0.2 million for the same period of the previous year. The analyst said the increase demonstrates sustained sales execution, placing Innovus on track to achieve its full-year guidance for $10 million - $15 million. The company is also expanding sales channels for its portfolio of 18 commercial products.…

WednesdayMay 31, 2017 2:28 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on May 31, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PRGE 37.04% – News: Board approves name change, 3:1 forward stock split LINU 36.16% – News: Posts Q1 2017 financial results STLT 14.87% – News: Initiates manufacturing process for Venodol WKHS 9.77% – News: Unveiling SureFly™ at the Paris Air Show on June 19 MBOT 9.29% – News: Receives Canadian patent covering a self-cleaning shunt HGBL 7.83% – News: Appoints national sales manager OWCP 6.65% – News: Enters partnership agreement with mediq VEND 6.58%…

WednesdayMay 31, 2017 1:05 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on CytoSorbents Corp. (NASDAQ: CTSO)

Following CytoSorbents Corp.’s (NASDAQ: CTSO) appointment of a new chief medical officer (CMO), Aegis Capital reiterated its ‘Buy’ rating and price target of $9 on shares of the company’s stock. The company recently named Dr. Eric G. Mortensen, M.D., Ph.D., as its new CMO, starting full-time tomorrow. Dr. Mortensen holds an M.D. from Harvard University and Massachusetts Institute of Technology Division of Health Sciences and Technology, and a Ph.D. in biophysics from the Harvard Graduate School of Arts and Sciences. Former CMO Dr. Robert H. Bartlett, M.D. will retire after nine years with the company, but will remain as a…

WednesdayMay 31, 2017 12:54 pm

NetworkNewsBreaks – MEI Pharma, Inc. (NASDAQ: MEIP) Exceeds Pre-Specified Response Rate Study of ME-401 in CLL and Follicular Lymphoma

Shares of MEI Pharma (NASDAQ: MEIP) are higher in mid-day trade on news that an independent Safety Review Committee has completed its pre-specified review of the first cohort of six evaluable patients in a phase Ib study of the company's potent and selective oral PI3K delta inhibitor, ME-401, in relapsed/refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma. "PI3K delta inhibitors have demonstrated clear activity in the treatment of CLL and follicular lymphoma, but at the expense of well-defined and substantial toxicities. We believe this provides an opportunity for a highly differentiated drug that is both effective and safe. Now we…

WednesdayMay 31, 2017 11:54 am

NetworkNewsBreaks – EMA Committee for Orphan Medicinal Products Recommends Designation for Catalyst Biosciences, Inc.’s (NASDAQ: CBIO) Factor IX

Shares of Catalyst Biosciences (NASDAQ: CBIO) are 15% higher this morning on news that a positive opinion recommending orphan medicinal product designation has been issued by the European Medicines Agency Committee (EMA) for Orphan Medicinal Products (COMP) regarding Catalyst’s CB 2679d for the treatment of hemophilia B. The clinical-stage biopharmaceutical company’s highly potent next-generation coagulation Factor IX variant demonstrated potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. Currently approved therapies rely on numerous intravenous infusions. “Obtaining orphan drug designation is an important part of our regulatory approval strategy for CB 2679d, and the…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks